about
Targeted therapy for hepatocellular carcinoma: novel agents on the horizonThe Reversal Effect and Its Mechanisms of Tetramethylpyrazine on Multidrug Resistance in Human Bladder CancerWeak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01).Ionic Liquid-assisted Synthesis of Celexocib Using Tris-(2-hydroxyethyl) Ammonium Acetate as an Efficient and Reusable Catalyst.Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.COX-2 in liver, from regeneration to hepatocarcinogenesis: what we have learned from animal models?Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study.Reversal of Multidrug Resistance by the Chinese Medicine Yiqi Jianpi Huaji Decoction and the Mechanism of Action in Human Gastric Cancer SGC7901/VCR Cells.Activating enhancer-binding protein-2α induces cyclooxygenase-2 expression and promotes nasopharyngeal carcinoma growth.Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2.Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project.Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death.A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatmentHepatocellular Carcinoma: Tumorigenesis and Prediction Markers.15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1.Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells.Inflammation and cancer: inhibiting the progression of residual hepatic VX2 carcinoma by anti-inflammatory drug after incomplete radiofrequency ablation.Study of the effects of cyclooxygenase-2 inhibitor on the promotion of hepatic tumorigenesis in rats fed a high fat diet.Oxidative stress and cell damage in a model of precancerous lesions and advanced hepatocellular carcinoma in rats.N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells.Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression.The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis.Dysregulation of apoptosis in hepatocellular carcinoma cells.Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells.Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis
P2860
Q27002288-324F5BB4-7C8A-4262-A3DF-8BBE577D371DQ28552489-FDDC8E24-B7ED-4CBB-A76C-4EB3C09C93EEQ33480709-E58AFF93-799E-4650-B11F-6AC43044F546Q33652215-BD4EB3A1-38FA-4B6C-BD1E-01636830D722Q33688897-6441CCEC-0FBF-409A-9253-638551D48302Q33756224-FDDEEE2A-64A4-4BC6-9583-0927CC63DCE9Q34775779-EA3C8075-02B6-4966-950D-88331544C6F8Q35071202-94E54BFC-77EC-4488-B9DC-46C02B903513Q35096634-7A765DE2-74A6-4A04-B064-4A5FEE7DFAD9Q35741600-E76A5010-0870-492A-995F-4341D748263AQ35906001-462AB500-A51A-4836-BBE8-30925CB1B490Q36140893-D8CAB750-5588-4290-9787-CE1CE51838F9Q36439797-D75BBC01-10D6-4F23-B104-5950A27E7422Q36444733-2B519CA0-4C62-4698-A896-6B2B32BD6D78Q37090409-5B97D355-A628-49DC-BD00-50CB9BD5D83BQ37215092-AEE92BAA-D0C5-4F87-95F8-E3103DD508CDQ37477526-AE62DD4D-E09B-40F2-AD5C-248C09252B00Q37549404-63C68CF2-2BC1-4FDF-8B22-C0B8F2FE5940Q38720783-21A7A663-D505-4128-9209-93F227903D56Q40044969-C7E75A06-3A3E-4A68-AF2B-3267DB276739Q40108804-E7AB6BE1-DA53-466E-A72E-28B7F5C2C355Q41680794-547E0ADA-3522-45FF-89C7-487BFCAABED4Q41880643-A78461B8-B7BC-4C5A-BEDC-530F9D17D2F8Q42204462-1CD6D08F-9792-45B1-A0D5-E43950CCEE40Q42364441-BCF76C00-0BAC-4B93-BF9A-8A8BF89A8DD1Q43166036-6254DF56-8368-4873-B60A-B9FC75F1230EQ54939991-B7EE2E9B-947A-4489-B25F-5777353AACE0Q58777735-D1C521A7-8604-430C-B2EF-2BA7A80D1AA1
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Cyclooxygenases in hepatocellular carcinoma.
@en
Cyclooxygenases in hepatocellular carcinoma.
@nl
type
label
Cyclooxygenases in hepatocellular carcinoma.
@en
Cyclooxygenases in hepatocellular carcinoma.
@nl
prefLabel
Cyclooxygenases in hepatocellular carcinoma.
@en
Cyclooxygenases in hepatocellular carcinoma.
@nl
P2860
P356
P1476
Cyclooxygenases in hepatocellular carcinoma
@en
P2093
Giuseppe Montalto
Melchiorre Cervello
P2860
P304
P356
10.3748/WJG.V12.I32.5113
P407
P577
2006-08-01T00:00:00Z